Identifying biomarkers for early diagnosis of Alzheimer's disease
Official title: Study on Body Fluid, Gene and Neuroimaging Biomarkers for Early Diagnosis of Alzheimer's Disease
Run by Capital Medical University · NCT04575337 · Data updated 2026-11-12
This study is trying to find early signs of Alzheimer's disease by looking at a large group of older people in China to help diagnose and treat the condition sooner.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 6000 (estimated) |
| Sponsor | Capital Medical University Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | May 28, 2020 |
| Main results expected | June 30, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | March 23, 2026 |
| Trial ID | NCT04575337 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are elderly individuals aged 18 and older, including those diagnosed with Alzheimer's disease, mild cognitive impairment, or those with normal cognitive function.
✕Probably not a fit
Patients under the age of 18 or those with significant medical or psychiatric illnesses may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to establish a large population-based cohort of elderly individuals in China, including those with Alzheimer's disease (AD), mild cognitive impairment (MCI), and normal cognitive function. It will collect clinical, cognitive, genetic, neuroimaging, and biospecimen data to identify specific biomarkers associated with different stages of AD. The study will also develop risk prediction models to forecast the onset and progression of AD over a five-year follow-up period. By employing standardized assessment protocols, the project seeks to enhance early diagnosis and intervention strategies for Alzheimer's disease.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate diagnosis of Alzheimer's disease, allowing for timely interventions.
How similar studies have gone: Other studies have shown promise in identifying biomarkers for Alzheimer's disease, but this approach focuses on a comprehensive population-based cohort, making it a novel effort.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Written informed consent obtained from participant or legal guardian prior to any study-related procedures. * Aged 18 (inclusive) or older. * Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD is made using the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS- ADRDA) or National Institute on Aging and the Alzheimer's Assocation (NIA-AA) criteria. A diagnosis of mild cognitive impairment (MCI) is assigned according to Petersen criteria. A diagnosis of pre-MCI group is assigned by β-Amyloid positive or APOE ε4 carrier or complains of cognitive impairment, but not up to MCI or cognitive impairment. Normal cognitive function assessed/evaluated by MMSE, CDR and other cognitive function scales. * Follow up 5 years and collect the information. Exclusion Criteria: * Under age 18. * Medical or psychiatric illness that would interfere in completing initial and follow-up visits. * No one can serve as a study informant. * With current or past neurological or psychiatric illnesses such as schizophrenia, epilepsy, brain tumors, severe head trauma and other diseases which can induce dementia. * Refused to complete a cognitive test and provide biospecimen. * With history of alcohol or drug abuse.
Where it's running
-
Xuanwu Hospital of Capital Medical University
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Jianping Jia, Doctor
- Email: jiajp@vip.126.com
- Phone: #8610-83199449
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood biomarker cohort for memory disorders in older adults
This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.
-
Tau changes after hip or knee replacement surgery
Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.
-
Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Mild Alzheimer's Dementia
This study will test whether a low-dose brain radiation treatment using HeLaXON helps people with mild Alzheimer's dementia improve or stabilize thinking and daily function.
-
Cervical lymphatic surgery to see if it helps people with mild Alzheimer’s
We’re testing a surgical approach in people with mild Alzheimer’s to see if creating alternative neck lymph drainage routes can affect brain biomarkers and daily function.
-
Transcranial random noise stimulation for behavioral and psychological symptoms in Alzheimer's disease
This trial tests whether high-frequency transcranial random noise stimulation can help people with early Alzheimer's disease who have BPSD, compared to a sham treatment.
-
Testing LY4405094 in healthy people and people with Alzheimer’s disease
This study tests LY4405094 to see if it is safe and how it behaves in the body, including how it reaches the brain fluid in healthy participants and how it affects a brain protein in people with Alzheimer's disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.